Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2025 16:25 ET | Source: Robbins LLP

VTRS Investors: Robbins LLP Reminds Viatris Inc. Stockholders of the Class Action Lawsuit on Behalf of Investors

Robbins LLP is Investigating Allegations that Viatris Inc. (VTRS) Misled Investors Regarding the Impact of the Failed Inspection of its Indore Facility
April 16, 2025 16:14 ET | Source: Robbins LLP

Robbins LLP Reminds VTRS Stockholders With Large Losses to Contact the Firm for Information About Leading the Class Action Lawsuit Against Viatris Inc.

Robbins LLP is Investigating Allegations that Viatris Inc. (VTRS) Misled Investors Regarding the Impact of the Failed Inspection of its Indore Facility
March 31, 2025 14:14 ET | Source: Robbins LLP

Actinium Pharmaceuticals, Inc. Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Against ATNM

Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B
March 18, 2025 18:15 ET | Source: Robbins LLP

NMRA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the Neumora Therapeutics, Inc. (NMRA) Class Action

Robbins LLP is Investigating Allegations that Neumora Therapeutics, Inc. (NMRA) Misled Investors in the Offering Documents in Support of its IPO
March 18, 2025 18:09 ET | Source: Robbins LLP

GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action

Robbins LLP is Investigating Allegations that GSK PLC (GSK) Misled Investors Regarding its Recall of Zantac
March 12, 2025 17:49 ET | Source: Robbins LLP

Marvai LifeSciences Holdings, Inc. Shareholders with Large Losses are Encouraged to Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Lawsuit Against MRVI

Robbins LLP is Investigating Allegations that Maravai LifeSciences Holdings, Inc. (MRVI) Intentionally Recorded Unearned Revenues
March 11, 2025 18:23 ET | Source: Robbins LLP

NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for Information

Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo’s Phase 3 CagriSema Study on Obesity
March 11, 2025 18:12 ET | Source: Robbins LLP

EPIX Shareholders Have an Opportunity to Lead the Class Action Against ESSA Pharma Inc. – Contact Shareholder Rights Law Firm Robbins LLP for Information

Robbins LLP is Investigating Allegations that ESSA Pharma Inc. (EPIX) Misled Investors Regarding the Efficacy of its Drug Candidate Masofaniten
February 18, 2025 20:31 ET | Source: Robbins LLP

RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Robbins LLP is Investigating Allegations that Revance Therapeutics, Inc. (RVNC) Misled Investors Regarding its Business Prospects
February 14, 2025 17:33 ET | Source: Robbins LLP

EPIX STOCK NEWS: EPIX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Essa Pharma Inc.

Robbins LLP is Investigating Allegations that ESSA Pharma Inc. (EPIX) Misled Investors Regarding the Efficacy of its Drug Candidate Masofaniten

Next Page keyboard_arrow_right